Bentham Science Publishers, Recent Patents on Inflammation and Allergy Drug Discovery, 3(5), p. 178-183
DOI: 10.2174/187221311797264928
Full text: Download
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. New different pharmacological approaches to decrease inflammation of the airways and consequently disease progression and increase airway obstruction reversibility have been developed. In the present article, we review the new patents on phosphoinositide 3 kinase and NFκb inhibitors for future therapies.